{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(2)"],"submitter":["Barmade MA"],"funding":["University Grants Commission","Department of Biotechnology, Ministry of Science and Technology, India"],"pubmed_abstract":["The emergence of drug resistance against the frontline antimalarials is a major challenge in the treatment of malaria. In view of emerging reports on drug-resistant strains of <i>Plasmodium</i> against artemisinin combination therapy, a dire need is felt for the discovery of novel compounds acting against novel targets in the parasite. In this study, we identified a novel series of quinolinepiperazinyl-aryltetrazoles (QPTs) targeting the blood stage of <i>Plasmodium</i>. <i>In vitro</i> anti-plasmodial activity screening revealed that most of the compounds showed IC<sub>50</sub> < 10 μM against chloroquine-resistant <i>Pf</i>INDO strain, with the most promising lead compounds 66 and 75 showing IC<sub>50</sub> values of 2.25 and 1.79 μM, respectively. Further, compounds 64-66, 68, 75-77 and"],"journal":["RSC medicinal chemistry"],"pagination":["572-594"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10880932"],"repository":["biostudies-literature"],"pubmed_title":["Novel quinolinepiperazinyl-aryltetrazoles targeting the blood stage of <i>Plasmodium falciparum</i>."],"pmcid":["PMC10880932"],"pubmed_authors":["Yadav MR","Rana B","Sahal D","Barmade MA","Agrawal P","Rajput SR","Murumkar PR"],"additional_accession":[]},"is_claimable":false,"name":"Novel quinolinepiperazinyl-aryltetrazoles targeting the blood stage of <i>Plasmodium falciparum</i>.","description":"The emergence of drug resistance against the frontline antimalarials is a major challenge in the treatment of malaria. In view of emerging reports on drug-resistant strains of <i>Plasmodium</i> against artemisinin combination therapy, a dire need is felt for the discovery of novel compounds acting against novel targets in the parasite. In this study, we identified a novel series of quinolinepiperazinyl-aryltetrazoles (QPTs) targeting the blood stage of <i>Plasmodium</i>. <i>In vitro</i> anti-plasmodial activity screening revealed that most of the compounds showed IC<sub>50</sub> < 10 μM against chloroquine-resistant <i>Pf</i>INDO strain, with the most promising lead compounds 66 and 75 showing IC<sub>50</sub> values of 2.25 and 1.79 μM, respectively. Further, compounds 64-66, 68, 75-77 and","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Feb","modification":"2026-06-03T00:24:31.145Z","creation":"2025-04-04T23:31:40.049Z"},"accession":"S-EPMC10880932","cross_references":{"pubmed":["38389888"],"doi":["10.1039/d3md00417a"]}}